(RTTNews) – Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medication supplier, and INTERLINK Care Administration, Inc. introduced Thursday an settlement designed to boost schooling and entry to hereditary most cancers testing for CancerCARE for Life members.
The settlement allows a couple of million people inside CancerCARE’s community to evaluate their eligibility for the MyRisk take a look at by taking the MyGeneHistory quiz, a guideline-based on-line affected person screening software.
In the event that they meet standards, they are often directed to a clinician who can order the MyRisk with RiskScore Hereditary Most cancers Check on their behalf. Sufferers who take the MyRisk take a look at can then overview their outcomes with a Myriad genetic counselor.
Myriad’s Breast Most cancers Danger Evaluation Program options the MyRisk with RiskScore Hereditary Most cancers Check and polygenic danger prediction take a look at for all ancestries. MyRisk evaluates 48 genes related to hereditary most cancers danger to determine genetic modifications related to an elevated most cancers danger for 11 totally different cancers.
It contains MyGeneHistory, a web based screening software that helps assess if a affected person meets medical tips for hereditary most cancers testing.
This system additionally contains affected person schooling about genetic testing and a information on the way to acquire household historical past of sure cancers.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
